Amarin Stock Price, News & Analysis

Amarin Corporation plc (NASDAQ:AMRN) announced preliminary unaudited total net revenue for 2020 estimated at $610 million, marking a 42% increase from 2019. This growth was primarily driven by increased prescriptions of VASCEPA® despite COVID-19 challenges. The company ended 2020 with over $550 million in cash and no debt. Amarin is preparing for the regulatory approval of VASCEPA in Europe and aims for a commercial launch in 2021. The company plans to present further details at the J.P. Morgan Healthcare Conference on January 12, 2021.

Amarin Corporation plc has announced that its president and CEO, John F. Thero, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, from 2:00 to 2:40 p.m. Eastern Time. A live audio webcast will be accessible at amarincorp.com for 30 days following the event.

Amarin focuses on cardiovascular health with its lead product, VASCEPA (icosapent ethyl), currently prescribed in the U.S., Canada, Lebanon, and the UAE. The company is pursuing further regulatory approvals in China, Europe, and the Middle East.

Amarin Corporation (NASDAQ:AMRN) presented critical findings related to VASCEPA® (icosapent ethyl) during the National Lipid Association Scientific Sessions 2020. Key highlights include a significant correlation between eicosapentaenoic acid (EPA) levels and improved cardiovascular outcomes, showcasing a 400% increase from baseline in a prominent trial. Additionally, the VASCEPA COVID-19 CardioLink-9 Trial indicated a 25% reduction in high-sensitivity C-reactive protein (hsCRP) among COVID-19 patients, suggesting VASCEPA may help alleviate symptoms while demonstrating good safety and tolerability.

Amarin Corporation announces positive results from the VASCEPA COVID-19 CardioLink-9 Trial, showcasing a 25% reduction in high-sensitivity C-reactive protein (hsCRP) and a 52% reduction in patient-reported COVID-19 symptoms compared to usual care. Conducted on 100 symptomatic outpatients, the trial demonstrated VASCEPA's potential as a therapeutic option in COVID-19, with promising short-term safety data. Larger follow-up studies are planned, expected to be completed by 2021. A webcast discussing these findings is scheduled for December 14, 2020.

Amarin Corporation has announced significant research findings to be showcased at the NLA Scientific Sessions 2020 from December 10-12, 2020. These include two Late Breaker presentations and six e-Posters centered on VASCEPA (icosapent ethyl), particularly its efficacy in cardiovascular risk reduction. Notably, the results from the COVID-19 CardioLink-9 trial will also be highlighted. Amarin emphasizes its commitment to support scientific research that explores the broader public health implications of VASCEPA.

Amarin Corporation has filed a patent infringement lawsuit against Hikma Pharmaceuticals for allegedly infringing on three U.S. patents related to VASCEPA, a prescription drug intended for reducing cardiovascular risk.

The lawsuit, initiated in the United States District Court in Delaware, claims Hikma engaged in unlawful activities by making and selling generic icosapent ethyl capsules. Amarin seeks monetary damages and a permanent injunction to stop Hikma's actions, asserting its rights to intellectual property developed over a decade.

Amarin Corporation plc (NASDAQ:AMRN) announced that CEO John F. Thero will participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference from December 1-3, 2020. Thero's presentation is set for December 2, 2020, at 10:00 AM ET. A live audio webcast of the session will be available on Amarin's website and accessible for 30 days. Amarin focuses on developing therapeutics to improve cardiovascular health, with its lead product, VASCEPA® (icosapent ethyl), approved in select countries.

Amarin Corporation (NASDAQ:AMRN) announced positive results from the Phase 3 clinical trial EDPC003R01, assessing VASCEPA (icosapent ethyl) in Chinese patients with very high triglyceride levels (≥500 mg/dL). The trial demonstrated a statistically significant median triglyceride reduction of 19.9% with a 4 grams per day dosage, without increasing low-density lipoprotein cholesterol (LDL-C). The results support upcoming regulatory submission by Amarin's partner, Edding, for VASCEPA's approval in China, addressing a significant medical need amidst rising hypertriglyceridemia rates.

Amarin Corporation (NASDAQ:AMRN) presented new data on VASCEPA (icosapent ethyl) at the AHA Virtual Scientific Sessions 2020, reinforcing its effectiveness in reducing major adverse cardiovascular events (MACE) in high-risk patients. Key findings include the unique mechanism of action of eicosapentaenoic acid (EPA) and significant outcomes from the REDUCE-IT trial demonstrating a 24% reduction in MACE for patients with a history of coronary artery bypass grafting. The data supports VASCEPA's cost-effectiveness and its potential for broader use in preventive cardiovascular care.